SG170020A1 - The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron - Google Patents

The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Info

Publication number
SG170020A1
SG170020A1 SG201101266-3A SG2011012663A SG170020A1 SG 170020 A1 SG170020 A1 SG 170020A1 SG 2011012663 A SG2011012663 A SG 2011012663A SG 170020 A1 SG170020 A1 SG 170020A1
Authority
SG
Singapore
Prior art keywords
iron
deferiprone
treat
methods
friedreich ataxia
Prior art date
Application number
SG201101266-3A
Other languages
English (en)
Inventor
Arnold Munnich
Michael Spino
Ioav Cabantchik
Original Assignee
Arnold Munnich
Michael Spino
Ioav Cabantchik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arnold Munnich, Michael Spino, Ioav Cabantchik filed Critical Arnold Munnich
Publication of SG170020A1 publication Critical patent/SG170020A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201101266-3A 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron SG170020A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22

Publications (1)

Publication Number Publication Date
SG170020A1 true SG170020A1 (en) 2011-04-29

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201101266-3A SG170020A1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Country Status (24)

Country Link
US (3) US20070197649A1 (pl)
EP (1) EP1991225B1 (pl)
JP (1) JP5730466B2 (pl)
KR (1) KR20080104329A (pl)
CN (1) CN101420954A (pl)
AU (1) AU2007219009B2 (pl)
BR (1) BRPI0708211A2 (pl)
CA (1) CA2642778A1 (pl)
DK (1) DK1991225T3 (pl)
ES (1) ES2441065T3 (pl)
IL (1) IL193598A (pl)
MA (1) MA30266B1 (pl)
MX (1) MX2008010824A (pl)
MY (1) MY151412A (pl)
NZ (1) NZ570730A (pl)
PL (1) PL1991225T3 (pl)
PT (1) PT1991225E (pl)
RS (1) RS53225B (pl)
RU (1) RU2008137604A (pl)
SG (1) SG170020A1 (pl)
SI (1) SI1991225T1 (pl)
TN (1) TNSN08338A1 (pl)
UA (1) UA95099C2 (pl)
WO (1) WO2007095728A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991225B1 (en) * 2006-02-22 2013-11-06 Apotex Technologies Inc. The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
UY30986A1 (es) 2007-03-28 2008-09-02 Apotex Technologies Inc Derivados fluorinados de deferiprona
WO2009129592A1 (en) 2008-04-25 2009-10-29 Apotex Technologies Inc. Liquid formulation for deferiprone with palatable taste
EP2389179A4 (en) * 2009-01-26 2012-08-29 Michael Spino USE OF DEFERPRONE FOR THE TREATMENT AND PREVENTION OF IRON-RELATED EYE DISORDERS
MX2012000247A (es) 2009-07-03 2012-03-26 Apotex Technologies Inc Derivados fluorados de 3-hidroxipiridin-4-onas.
US20120157464A1 (en) 2009-07-23 2012-06-21 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2611457B1 (en) 2010-08-30 2014-03-19 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (en) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
US20200253945A1 (en) 2017-10-25 2020-08-13 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) * 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
EP1991225B1 (en) * 2006-02-22 2013-11-06 Apotex Technologies Inc. The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Also Published As

Publication number Publication date
TNSN08338A1 (en) 2009-12-29
US20130190365A1 (en) 2013-07-25
EP1991225A1 (en) 2008-11-19
AU2007219009A1 (en) 2007-08-30
CN101420954A (zh) 2009-04-29
IL193598A0 (en) 2009-08-03
UA95099C2 (ru) 2011-07-11
MY151412A (en) 2014-05-30
US20070197649A1 (en) 2007-08-23
JP5730466B2 (ja) 2015-06-10
MA30266B1 (fr) 2009-03-02
ES2441065T3 (es) 2014-01-31
RU2008137604A (ru) 2010-03-27
PT1991225E (pt) 2014-02-13
SI1991225T1 (sl) 2014-02-28
NZ570730A (en) 2013-05-31
MX2008010824A (es) 2009-06-08
DK1991225T3 (da) 2013-12-16
KR20080104329A (ko) 2008-12-02
EP1991225A4 (en) 2009-07-29
RS53225B (en) 2014-08-29
BRPI0708211A2 (pt) 2011-05-17
IL193598A (en) 2012-08-30
EP1991225B1 (en) 2013-11-06
CA2642778A1 (en) 2007-08-30
JP2009527506A (ja) 2009-07-30
US20090023784A1 (en) 2009-01-22
WO2007095728A1 (en) 2007-08-30
PL1991225T3 (pl) 2014-04-30
AU2007219009B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
SG170020A1 (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
MX2010004897A (es) Forma de dosificacion oralmente desintegrada.
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
BRPI0414254A (pt) composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação
NO20065662L (no) Esterlinkede makrolider nyttige for behandlingen av mikrobielle infeksjoner
MX2022007276A (es) Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas.
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
NZ595629A (en) Methods for preventing and/or treating lysosomal storage disorders
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
MY148955A (en) Carbamoly-cyclohexanes for treating acute mania
MX2016001457A (es) Medicamentos terapeuticos de matriz extracelular endotelial corneal.
PL1680112T3 (pl) N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
CN205698180U (zh) 一种肩手一体式约束带
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
TN2010000249A1 (en) New medical use of 3-(2,2,2-trimethylhydrazinium ) propionate salts
CY1114714T1 (el) Η χρηση δεφεριπρονης και μεθοδοι για την θεραπεια και/ή προληψη της αταξιας friedreich που προκυπτει απο ενδοκυτταρικη κακη διαχειριση σιδηρου
NO20084999L (no) Fremgangsmate for behandling av arvelig hemokromatose
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2004012677A3 (en) Methods and compositions to treat conditions associated with neovascularization
WO2011044434A3 (en) A composition and a method of treating cns disorders and hyperpigmentation
EA201490173A1 (ru) Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции